Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The chromaffin granule amine transporter (CGAT), also known as vesicular monoamine transporter 1 (VMAT1), is a membrane protein responsible for packaging monoamine neurotransmitters into secretory vesicles within adrenal chromaffin cells and other aminergic cells. This process is essential for the regulated storage and release of neurotransmitters such as norepinephrine, epinephrine, dopamine, and serotonin. CGAT mediates the active transport of cytosolic monoamines into storage vesicles by exchanging one cationic monoamine with two intravesicular protons, relying on a proton gradient generated by vacuolar-type H+-ATPase. Inhibition of CGAT can lead to depletion of monoamine stores and associated side effects.
Inhibits vesicular monoamine uptake via competitive or allosteric mechanisms.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chromaffin Granule Amine Transporter (CGAT).